medigraphic.com
ISSN 2448-8909 (Print)

2024, Number 2

<< Back Next >>

Med Crit 2024; 38 (2)

Point of care thromboelastography in patients with severe pneumonia due to SARS-CoV-2 in the Intensive Care Unit

Martínez GEX, Jesús MF, Salazar MA, Morales SG, Herrera MBE, Sharpe BEP

Language: Spanish
References: 27
Page: 80-89
PDF size: 402.54 Kb.


ABSTRACT

Introduction: infection by the new coronavirus SARS-CoV-2 has been characterized worldwide by presenting a coagulopathy associated with the severity of the condition with an increase in morbidity and mortality. The severe inflammatory state secondary to infection leads to a severe haemostasis disorder typically seen in patients with sepsis and has recently been described as sepsis induced coagulopathy (SIC). This has been poorly documented in patients with infection by this new coronavirus. Material and methods: a prospective study was carried out, in which patients diagnosed by PCR (Protein Chain Reaction) for SARS-CoV-2 infection and severe pneumonia by ATS (American Thoracic Society) Score criteria were admitted, where performed a thromboelastography (TEG) at the patient's bedside (point of care thromboelastography), in the adult intensive care unit (ICU). Results: the results show a tendency to hypercoagulability patterns, the most frequent in 42% of the samples studied, was the increase in the maximum amplitude, which is associated with platelet hypercoagulability and in 21.4% the decreased reaction time ® related to enzymatic hypercoagulability. Conclusions: the infection by this new coronavirus induces a procoagulant state by activating the platelet and the use of platelet antiaggregant could be recommended. The hypercoagulability patterns assessed in this study were not restricted to platelet hypercoagulability, so a larger sample is required to be conclusive.


REFERENCES

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.

  2. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738-1742.

  3. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 2020;46(8):1603-1606.

  4. Berlin D, Gulick R, Martinez F. Severe Covid-19. N Engl J Med. 2020;383:2451-2460.

  5. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. An official clinical practice guideline of the American Thoracic Society and infectious diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67.

  6. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046.

  7. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994.

  8. Galvez K, Cortez C. Tromboelastografía: nuevos conceptos en la fisiología de la hemostasia y su correlación con la coagulopatía asociada al trauma. Rev Colomb Anestesiol. 2012;40(3):224-230.

  9. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. Erratum in: Clin Infect Dis. 2017;64(9):1298. Erratum in: Clin Infect Dis. 2017;65(8):1435. Erratum in: Clin Infect Dis. 2017;65(12):2161.

  10. Mucha SR, Dugar S, McCrae K, Joseph D, Bartholomew J, Sacha GL, et al. Coagulopathy in COVID-19: manifestations and management. Cleve Clin J Med. 2020;87(8):461-468.

  11. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020;48(9):1358-1364.

  12. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54-67.

  13. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.

  14. Gattinoni L, Taccone P, Carlesso E, Marini JJ. Prone position in acute respiratory distress syndrome. rationale, indications, and limits. Am J Respir Crit Care Med. 2013;188(11):1286-1293.

  15. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360.

  16. Medcalf RL, Keragala CB, Myles PS. Fibrinolysis and COVID-19: a plasmin paradox. J Thromb Haemost. 202018(9):2118-2122.

  17. Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S, et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 Infection. J Am Coll Surg. 2020;231(2):193-203.e1.

  18. Bouadma L, Lescure FX, Lucet JC, Yazdanpanah Y, Timsit JF. Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists. Intensive Care Med. 2020;46(4):579-582.

  19. Costanzo L, Palumbo FP, Ardita G, Antignani PL, Arosio E, Failla G, et al. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. J Vasc Surg Venous Lymphat Disord. 2020;8(5):711-716.

  20. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. Guía ESC 2019 para el diagnóstico y tratamiento de la embolia pulmonar aguda. Rev Esp Cardiol. 2020;73(6):497.e1-497.e58.

  21. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.

  22. Elizalde GJJ, Fortuna CJA, Luviano GJA, Mendoza RVM, Mijangos MJC, Olivares DEM, et al. Guía para la Atención del Paciente Crítico con Infección por COVID-19. Med Crit. 2020;34(1):7-42.

  23. Ten Cate H. Thrombosis management in times of COVID-19 epidemy; a dutch perspective. Thrombosis J. 2020;18:7.

  24. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950-2973.

  25. Vivas D, Roldán V, Esteve-Pastor MA, Roldán I, Tello-Montoliu A, Ruiz-Nodar JM, et al. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología [Recommendations on antithrombotic treatment during the COVID-19 pandemic. position statement of the working group on cardiovascular thrombosis of the spanish society of cardiology]. Rev Esp Cardiol. 2020;73(9):749-757.

  26. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S-47S. Erratum in: Chest. 2012;141(4):1129. Dosage error in article text. Erratum in: Chest. 2012;142(6):1698.

  27. Hardy M, Lecompte T, Douxfils J, Lessire S, Dogné JM, Chatelain B, et al. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thromb J. 2020;18:17.




2020     |     www.medigraphic.com